CA2929650C - Derives de 4-(indol-3-yl)pyrazole, compositions pharmaceutiques et procedes d'utilisation - Google Patents

Derives de 4-(indol-3-yl)pyrazole, compositions pharmaceutiques et procedes d'utilisation Download PDF

Info

Publication number
CA2929650C
CA2929650C CA2929650A CA2929650A CA2929650C CA 2929650 C CA2929650 C CA 2929650C CA 2929650 A CA2929650 A CA 2929650A CA 2929650 A CA2929650 A CA 2929650A CA 2929650 C CA2929650 C CA 2929650C
Authority
CA
Canada
Prior art keywords
pyrazol
fluoro
indol
indole
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2929650A
Other languages
English (en)
Other versions
CA2929650A1 (fr
Inventor
Stefano Crosignani
Sandra CAUWENBERGHS
Frederik Deroose
Gregory DRIESSENS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Iteos Belgium SA
Original Assignee
Iteos Therapeutics SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/076,016 external-priority patent/US9126984B2/en
Application filed by Iteos Therapeutics SA filed Critical Iteos Therapeutics SA
Publication of CA2929650A1 publication Critical patent/CA2929650A1/fr
Application granted granted Critical
Publication of CA2929650C publication Critical patent/CA2929650C/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
CA2929650A 2013-11-08 2014-11-07 Derives de 4-(indol-3-yl)pyrazole, compositions pharmaceutiques et procedes d'utilisation Expired - Fee Related CA2929650C (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US14/076,016 2013-11-08
EP13192224 2013-11-08
EP13192224.7 2013-11-08
US14/076,016 US9126984B2 (en) 2013-11-08 2013-11-08 4-(indol-3-yl)-pyrazole derivatives, pharmaceutical compositions and methods for use
BE201400845 2014-11-03
BE2014/0845 2014-11-03
PCT/EP2014/074099 WO2015067782A1 (fr) 2013-11-08 2014-11-07 Dérivés de 4-(indol-3-yl)pyrazole, compositions pharmaceutiques et procédés d'utilisation

Publications (2)

Publication Number Publication Date
CA2929650A1 CA2929650A1 (fr) 2015-05-14
CA2929650C true CA2929650C (fr) 2017-08-22

Family

ID=53040940

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2929650A Expired - Fee Related CA2929650C (fr) 2013-11-08 2014-11-07 Derives de 4-(indol-3-yl)pyrazole, compositions pharmaceutiques et procedes d'utilisation

Country Status (4)

Country Link
EP (1) EP3066090A1 (fr)
JP (1) JP2016535097A (fr)
CA (1) CA2929650C (fr)
WO (1) WO2015067782A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI695831B (zh) 2014-09-13 2020-06-11 香港商南北兄弟藥業投資有限公司 Ｃｒｔｈ２拮抗劑化合物及其用途
RS62112B1 (sr) * 2016-04-29 2021-08-31 Bayer Pharma AG Sinteza indazola
EP3269714A1 (fr) 2016-07-13 2018-01-17 Netherlands Translational Research Center B.V. Inhibiteurs de tryptophane 2,3-dioxygénase
CN109952300B (zh) 2016-09-24 2022-01-18 百济神州有限公司 5或8-取代的咪唑并[1,5-a]吡啶
US20230391786A1 (en) * 2022-06-02 2023-12-07 Eli Lilly And Company cGAS INHIBITORS

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2862647B1 (fr) * 2003-11-25 2008-07-04 Aventis Pharma Sa Derives de pyrazolyle, procede de preparation et intermediaires de ce procede a titre de medicaments et de compositions pharmaceutiques les renfermant
GB0516156D0 (en) * 2005-08-05 2005-09-14 Eisai London Res Lab Ltd JNK inhibitors
WO2010008427A1 (fr) * 2008-04-11 2010-01-21 Ludwig Institute For Cancer Research Ltd. Catabolisme du tryptophane dans le traitement et le diagnostic du cancer
CA2772371A1 (fr) 2009-05-27 2010-12-02 F. Hoffmann-La Roche Ag Composes bicycliques indole-pyrimidine inhibiteurs de pi3k selectifs pour p110 delta et leurs procedes d'utilisation
CN103947645B (zh) 2009-10-12 2016-07-06 拜尔农作物科学股份公司 作为杀虫剂的1-(吡啶-3-基)-吡唑和1-(嘧啶-5-基)-吡唑
WO2011163527A1 (fr) * 2010-06-23 2011-12-29 Vertex Pharmaceuticals Incorporated Dérivés de pyrrolo-pyrazine utiles en tant qu'inhibiteurs de l'atr kinase

Also Published As

Publication number Publication date
CA2929650A1 (fr) 2015-05-14
WO2015067782A1 (fr) 2015-05-14
EP3066090A1 (fr) 2016-09-14
JP2016535097A (ja) 2016-11-10

Similar Documents

Publication Publication Date Title
US9126984B2 (en) 4-(indol-3-yl)-pyrazole derivatives, pharmaceutical compositions and methods for use
US20160263087A1 (en) Novel 4-(indol-3-yl)-pyrazole derivatives, pharmaceutical compositions and methods for use
KR102013512B1 (ko) 신규 3-인돌 치환 유도체, 제약 조성물 및 사용 방법
US9758505B2 (en) 3-(indol-3-yl)-pyridine derivatives, pharmaceutical compositions and methods for use
CA2929650C (fr) Derives de 4-(indol-3-yl)pyrazole, compositions pharmaceutiques et procedes d'utilisation
CA2994917A1 (fr) Derives substitues par un 3-indole, compositions pharmaceutiques et leurs procedes d'utilisation
NO324519B1 (no) Alifatisk nitrogenholdig 5-kantet ring-forbindelse
KR20230171979A (ko) Bcl6 단백질 분해의 조절제 및 관련 사용 방법
CA2998705A1 (fr) Derives de 1-phenylpyrrolidin-2-one comme inhibiteurs de perk
IL293530A (en) Derivatives of 3-(5-methoxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione and their uses
WO2015155358A1 (fr) Inhibiteurs de mif
JP2019001715A (ja) 三環性化合物
JP2022543690A (ja) 架橋ヘテロシクリル置換ピリミジン化合物、その調製方法、及びその薬学的使用
WO2017018475A1 (fr) Dérivé de pyrazole condensé présentant un nouveau site de liaison et utilisation médicinale de celui-ci
EP2476682A1 (fr) Dérivés de 8-oxodihydropurine
CN117177974A (zh) 含咪唑稠环类衍生物、其制备方法及其在医药上的应用
EP3013333A1 (fr) Composés hétérocycliques et leurs méthodes d'utilisation pour le traitement de l'hépatite c
WO2021202775A1 (fr) Dérivés de n-(hétérocyclyl et hétérocyclylalkyl)-3-benzylpyridin-2-amine servant d'agonistes de sstr4
TW202409011A (zh) 人類呼吸道融合病毒及間質肺病毒抑制劑
CN117209501A (zh) 磺酰胺衍生物及其用途

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20160504

MKLA Lapsed

Effective date: 20181107